Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 5/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989199 | 0.87 | CYP17A1 (0.34) | CYP17A1CYP1A2KMOHTR2AHTR2C | |
| SCHEMBL24851750 | 0.81 | PDPK1 (0.34) | CYP17A1CYP1A2NT5EHTR2AHTR2C | |
| SCHEMBL24851097 | 0.81 | HTR2A (0.35) | CYP17A1CYP1A2NT5EKMOHTR2A | |
| SCHEMBL23994190 | 0.77 | KMO (0.55) | CYP17A1CYP1A2KMOHTR2AHTR2C | |
| SCHEMBL30701694 | 0.77 | HTR2A (0.42) | NT5EKMOHTR2AHTR2C | |
| SCHEMBL30224584 | 0.77 | NT5E (0.35) | NT5E | |
| SCHEMBL23994009 | 0.76 | HTR2A (0.33) | CYP17A1CYP1A2KMOHTR2AHTR2C | |
| SCHEMBL30224915 | 0.76 | HTR2A (0.33) | CYP17A1CYP1A2KMOHTR2AHTR2C | |
| SCHEMBL22888554 | 0.76 | RIPK1 (0.40) | NT5EKMOHTR2AHTR2CRIPK1 | |
| SCHEMBL23995512 | 0.76 | NT5E (0.36) | NT5ERIPK1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240279186-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240116928-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11919869-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | CYP17A1 59/4885CYP1A2 61/4885NT5E 3622/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | CYP17A1 4392/4885CYP1A2 3166/4885NT5E 3/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | CYP17A1 3414/4885CYP1A2 2027/4885NT5E 3/4885 |
| US-20250270174-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885NT5E 2/4885 |
| US-11919869-B2 | CD73 compounds | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885NT5E 2/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | CYP17A1 59/4885CYP1A2 61/4885NT5E 3622/4885 |
| US-20240116928-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1594/4885CYP1A2 891/4885NT5E 2/4885 |
| US-20240279186-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885NT5E 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.